Diagnostic Power of Cytokine M-CSF, Metalloproteinase 2 (MMP-2) and Tissue Inhibitor-2 (TIMP-2) in Cervical Cancer Patients Based on ROC Analysis.
Cervical cancer
M-CSF
MMP-2
TIMP-2
Tumor markers
Journal
Pathology oncology research : POR
ISSN: 1532-2807
Titre abrégé: Pathol Oncol Res
Pays: Switzerland
ID NLM: 9706087
Informations de publication
Date de publication:
Apr 2020
Apr 2020
Historique:
received:
06
03
2018
accepted:
20
02
2019
pubmed:
2
3
2019
medline:
1
4
2021
entrez:
2
3
2019
Statut:
ppublish
Résumé
Macrophage colony-stimulating factor (M-CSF), matrix metalloproteinase-2 (MMP-2) and its specific tissue inhibitor (TIMP-2) may play an important role in the pathogenesis of cancer disease. We investigated the plasma levels and diagnostic power (ROC curve analysis) of M-CSF, MMP-2, TIMP-2 and tumor markers CA 125 and SCC-Ag in cervical cancer (CC) patients as compared to control group. The study included 89 patients with cervical cancer. The control group consisted of 50 healthy, untreated women. The plasma levels of M-CSF, MMP-2 and TIMP-2 were determined using ELISA, CA 125 and SCC-Ag - by CMIA method. The median levels of M-CSF, TIMP-2, SCC-Ag and CA 125 in the entire group of CC were significantly different than compared to the healthy women group. MMP-2 showed the highest value of sensitivity from all examined parameters (in stage I of CC - 93.10%, II - 82.76%, III and IV - 96.88%, total group - 92.05%). The highest specificity was obtained by M-CSF (86%). The area under the ROC curve (AUC) of M-CSF (0.8051) was the largest of all the tested parameters (even higher than commonly used tumor markers) in the group of cervical cancer. The combination of M-CSF, MMP-2 or TIMP-2 with SCC antigen resulted in an increase AUCs in all cases (0.8760;0.7880;0.8081;respectively). The findings of this study suggest the usefulness of all examined parameters in the diagnostics of CC patients. Out of the tested substances, M-CSF also appears to be the best candidate for cancer diagnostics in all stages of the disease, based on ROC analysis.
Identifiants
pubmed: 30820752
doi: 10.1007/s12253-019-00626-z
pii: 10.1007/s12253-019-00626-z
pmc: PMC7242253
doi:
Substances chimiques
Biomarkers, Tumor
0
TIMP2 protein, human
0
Tissue Inhibitor of Metalloproteinase-2
127497-59-0
Macrophage Colony-Stimulating Factor
81627-83-0
MMP2 protein, human
EC 3.4.24.24
Matrix Metalloproteinase 2
EC 3.4.24.24
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
791-800Références
Clin Chim Acta. 2006 Sep;371(1-2):112-6
pubmed: 16631152
Int J Gynecol Cancer. 2015 Sep;25(7):1151-64
pubmed: 26207784
Int J Colorectal Dis. 2007 Jan;22(1):33-8
pubmed: 16520929
J Cell Commun Signal. 2012 Jun;6(2):87-95
pubmed: 22227894
Biochimie. 2005 Mar-Apr;87(3-4):287-97
pubmed: 15781315
Pol Merkur Lekarski. 2008 Jul;25(145):38-42
pubmed: 18839612
Cancer Res. 2006 Jan 15;66(2):605-12
pubmed: 16423985
J Gynecol Oncol. 2014 Apr;25(2):124-9
pubmed: 24761216
Ann Lab Med. 2016 May;36(3):223-9
pubmed: 26915610
Front Biosci. 2006 Jan 01;11:479-91
pubmed: 16146745
Folia Histochem Cytobiol. 2012 Jul 04;50(2):213-9
pubmed: 22763962
Biochim Biophys Acta. 2005 May 25;1755(1):37-69
pubmed: 15907591
Int J Biol Markers. 2012 Oct 08;27(3):e186-94
pubmed: 22865301
J Ovarian Res. 2015 May 03;8:27
pubmed: 25935153
Clin Lab. 2016 Sep 1;62(9):1661-1669
pubmed: 28164586
Invasion Metastasis. 1994-1995;14(1-6):234-45
pubmed: 7657516
J Immunol. 2003 Sep 1;171(5):2637-43
pubmed: 12928417
Semin Cancer Biol. 2010 Jun;20(3):161-8
pubmed: 20470890
Growth Factors. 2012 Dec;30(6):357-66
pubmed: 22988839
Growth Factors. 2013 Jun;31(3):98-105
pubmed: 23688065
Angiogenesis. 2014 Jul;17(3):573-85
pubmed: 24197832
J BUON. 2016 Mar-Apr;21(2):320-5
pubmed: 27273940
Clin Cancer Res. 2004 Nov 15;10(22):7621-8
pubmed: 15569994
Mediators Inflamm. 2016;2016:5962946
pubmed: 27445439
Anticancer Res. 2015 Feb;35(2):865-74
pubmed: 25667468
Ann Med. 1999 Feb;31(1):34-45
pubmed: 10219712
Endocr Relat Cancer. 2013 Oct 14;20(6):777-83
pubmed: 24016870
Medicine (Baltimore). 2016 Mar;95(9):e2675
pubmed: 26945355
Przegl Lek. 2007;64(12):987-90
pubmed: 18595499
Biochem Soc Trans. 2016 Apr 15;44(2):333-41
pubmed: 27068937
CA Cancer J Clin. 2015 Mar;65(2):87-108
pubmed: 25651787
Mol Cell Ther. 2014 Jun 03;2:17
pubmed: 26056585
Virol Sin. 2015 Apr;30(2):101-6
pubmed: 25910482
Biochim Biophys Acta. 2010 Jan;1803(1):55-71
pubmed: 20080133
Mol Cell Biochem. 2003 Nov;253(1-2):269-85
pubmed: 14619979
J Cancer Res Clin Oncol. 2014 Sep;140(9):1585-93
pubmed: 24804816
Womens Health Issues. 2016 Sep-Oct;26(5):574-83
pubmed: 27365286